What is the recommended follow-up for a patient presenting with hematuria?

Follow-up on Hematuria

All adults with gross hematuria require urgent urologic evaluation with cystoscopy and imaging, even if self-limited, while patients with microscopic hematuria need risk-stratified follow-up based on their initial evaluation results. 1

Initial Distinction: Gross vs. Microscopic Hematuria

The follow-up pathway fundamentally depends on whether hematuria is visible or microscopic:

• Gross hematuria: Carries 30-40% malignancy risk and mandates full urologic workup regardless of whether it resolves 2
• Microscopic hematuria: Defined as ≥3 RBCs per high-power field on properly collected specimen; carries 2.6-4% malignancy risk 2

Critical pitfall: Never dismiss gross hematuria as benign even if it self-resolves or occurs in patients on anticoagulation—these patients still require complete evaluation 1.

Follow-up After Negative Initial Evaluation

For Patients with Negative Workup and Persistent Microscopic Hematuria

The most recent 2025 AUA/SUFU guidelines recommend shared decision-making regarding repeat urinalysis, with most patients not requiring ongoing urologic monitoring after appropriate risk-stratified negative evaluation 3. This represents an evolution from older recommendations.

The specific follow-up schedule depends on risk stratification:

High-risk patients (age ≥60, >30 pack-year smoking history, >25 RBCs/HPF, history of gross hematuria):

• Consider repeat urinalysis at clinician and patient discretion
• Immediate re-evaluation if: gross hematuria develops, abnormal cytology, or new irritative voiding symptoms without infection 4

Intermediate-risk patients (age 50-59 for women/40-59 for men, 10-30 pack-years, 11-25 RBCs/HPF):

• Engage in shared decision-making about future UA monitoring
• No mandatory surveillance schedule if initial evaluation negative 5, 3

Low-risk patients (age <50 for women/<40 for men, <10 pack-years, 3-10 RBCs/HPF, no risk factors):

• May be discharged after negative repeat UA
• No further urologic follow-up needed 5, 3

Traditional Follow-up Protocol (Older Guidelines)

The 2001 AUA guidelines, while superseded, provided specific intervals that some clinicians still reference:

• Repeat urinalysis, cytology, and blood pressure at 6,12,24, and 36 months
• Discontinue monitoring after 3 years if no concerning findings develop 4

However, the 2025 guidelines explicitly move away from this rigid schedule, recognizing that repeated evaluations have minimal diagnostic yield and most patients can be safely discharged after appropriate initial evaluation 3.

Triggers for Immediate Re-evaluation

Regardless of initial risk category, urgent urologic re-evaluation is mandatory if any of the following occur:

1. Development of gross hematuria (even single episode)
2. Abnormal/atypical urinary cytology
3. New irritative voiding symptoms without documented infection
4. Significant increase in degree of microscopic hematuria 4, 5, 4

Special Populations Requiring Nephrology Referral

Refer to nephrology (not urology) if evidence suggests glomerular disease:

• Proteinuria >1,000 mg/24 hours (or >500 mg/24 hours if persistent/increasing)
• Red blood cell casts (virtually pathognomonic for glomerular bleeding)
• Dysmorphic RBCs (>80% dysmorphic suggests glomerular origin)
• Elevated serum creatinine with hematuria
• Hypertension developing with persistent hematuria 4

Important nuance: Patients can have both glomerular disease AND urologic pathology—glomerular findings do not exclude need for urologic evaluation 2.

What NOT to Do

Based on high-value care recommendations 1:

• Do not screen asymptomatic adults with urinalysis for cancer detection
• Do not obtain urinary cytology or molecular markers in initial evaluation
• Do not defer evaluation in patients on anticoagulation/antiplatelet therapy
• Do not accept dipstick alone—confirm with microscopy showing ≥3 RBCs/HPF before initiating workup

Practical Algorithm for Primary Care

1. Confirm true hematuria: Microscopy with ≥3 RBCs/HPF on properly collected specimen (exclude menstruation, recent exercise, infection, trauma) 1

2. Assess for glomerular disease: Check for proteinuria, RBC casts, dysmorphic RBCs, elevated creatinine → nephrology if present 4

3. Risk stratify using 2025 AUA criteria (age, sex, smoking history, degree of hematuria, gross hematuria history) 5, 3

4. Refer to urology for cystoscopy and imaging based on risk level:

   • All gross hematuria → immediate referral
   • High-risk microscopic hematuria → full evaluation
   • Intermediate-risk → full evaluation
   • Low-risk → may defer cystoscopy but obtain imaging; consider repeat UA first 5

5. After negative evaluation: Most patients discharged; high-risk patients may have repeat UA at discretion; all patients counseled on red-flag symptoms requiring immediate return 3

The key paradigm shift: Modern guidelines emphasize risk-stratified initial evaluation followed by discharge for most patients, rather than prolonged surveillance protocols, recognizing the low yield of repeated testing after appropriate negative workup 3.